A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies (NCT03329950) | Clinical Trial Compass
CompletedPhase 1
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
United States132 participantsStarted 2017-12-01
Plain-language summary
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Recurrent, locally advanced or metastatic melanoma (including mucosal and/or ocular), bladder/urothelial, non-small cell lung cancer, pancreatic adenocarcinoma, breast, colorectal, gastric, esophageal, renal cell, hepatic, ovarian fallopian or primary peritoneal carcinoma, head and neck, and cholangiocarcinoma. Additional tumor types (except primary CNS tumors) may be enrolled after discussion with, and approval from, the medical monitor.
✓. Must have received all standard of care therapies (approved or unapproved) as deemed appropriate by the treating physician. Patients who refuse standard therapy are excluded from the study.
✓. If of childbearing potential (male or female), agrees to practice an effective form of contraception during study treatment and for at least 3 months following last treatment
✓. Willingness to undergo a pre-treatment and on-treatment biopsy, if required.
✓. Advanced diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, or indolent B-cell lymphoma are also eligible.
✓. Lymphoma patients must have received ≥ 1 prior systemic therapy
✓. Patients must have documented progression while receiving anti-PD-1 or anti-PD-L1 based regimens for FDA approved indications
✓. Patients cannot have received more than one anti-PD-1 or anti-PD-L1 based regimen
Exclusion criteria
✕. History of severe hypersensitivity reactions to other monoclonal antibodies.
✕
What they're measuring
1
Safety and Tolerability of CDX-1140 as assessed by CTCAE v5.0
Timeframe: From first dose through 30 days after last dose
. Previous treatment with any anti-CD40 antibody or with FLT3L.
✕. Inadequate washout period from prior therapy as defined in the Protocol.
✕. Major surgery within 4 weeks prior to study treatment.
✕. Use of immunosuppressive medications within 4 weeks or systemic corticosteroids within 2 weeks prior to study treatment.
✕. Other prior malignancy, except for adequately treated basal or squamous cell skin cancer or in situ cancers. For all other cancers, the patient must be disease-free for at least 3 years to be allowed to enroll.
✕. Active, untreated central nervous system metastases.
✕. Active autoimmune disease or documented history of autoimmune disease.